The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
111 Michigan Ave. NW
Washington, DC 20010
The Peuropulmonary Blastoma (PPB) Research at Children's National Medical Center, in collaboration with the International PPB Registry (http://www.ppbregistry.org), the Washington University in St. Louis and over 60 families affected by PPB, is working to uncover how and why PPB begins. They welcome further participation from family members of children with PPB or PPB survivors who are not yet in the study. Pleuropulmonary blastoma (PPB) is a malignant tumor of the lung that affects young children. Most children with PPB develop their tumors in the first five years of life. The majority of children with the earliest form of the disease (Type I PPB) are curable with surgery and possibly chemotherapy. Children with the later forms (Type II or III PPB) have a much more difficult course.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.